中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 近代物理研究所
  3. 中国科学院近代物理研究所
Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells

文献类型：期刊论文

作者Zhang, Qianjing2,3,4; Di, Cuixia2,3,4; Yan, Junfang2,3,4; Wang, Fang2,3,4; Qu, Tao1; Wang, Yupei2,3,4; Chen, Yuhong2,3,4; Zhang, Xuetian2,3,4; Liu, Yang2,3,4; Yang, Hongying5
刊名ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
出版日期2019
卷号47期号:1页码:1273-1280
ISSN号2169-1401
关键词Alternative splicing apoptosis cancer pladienolide B p73 SF3b1
DOI10.1080/21691401.2019.1596922
英文摘要Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3b1 subunit of the spliceosome. There is considerable interest in the compound as a tool to study SF3b1 function in cancer. However, so far little information is available on the molecular mechanism of SF3b1 eliciting apoptosis in cancer cells. Here, we investigated the molecular mechanism of SF3b1 eliciting apoptosis in human cervical carcinoma cells. We demonstrated that inhibition of SF3b1 by pladienolide B inhibited proliferation of HeLa cells at low nanomolar concentrations in a dose- and time-dependent manner. It also induced G2/M phase arrest and significant rise of apoptotic cells. Moreover, it is indicated that inhibition of SF3b1 by pladienolide B induced Tap73/Delta Np73 expression and consequently down-regulated Bax/Bcl-2 ratio, cytochrome c release and caspase-3 expression. Thus, our results showed that SF3b1 plays a pivotal role in cycle arrest, apoptosis induction, and p73 splicing in human cervical carcinoma cells, suggesting that SF3b1 could be used as a potential candidate for cervical cancer therapy.
WOS关键词IN-VITRO ; TARGET ; CANCER ; PATHWAY ; TAP73/DELTA-NP73 ; SPLICEOSOME ; PROGNOSIS ; PROTEINS ; RATIO ; LIFE
资助项目National Key R&D Project of the Chinese Ministry of Science and Technology[2016YFC0904600] ; National Key R&D Project of the Chinese Ministry of Science and Technology[2018YFE020524] ; Key Program of the National Natural Science Foundation of China[U1432248] ; Key Program of the National Natural Science Foundation of China[U1632270] ; National Natural Science Foundation of China[11675234] ; National Natural Science Foundation of China[11575262] ; Natural Science Foundation of Gansu[17JR5RA310]
WOS研究方向Biotechnology & Applied Microbiology ; Engineering ; Materials Science
语种英语
出版者TAYLOR & FRANCIS LTD
WOS记录号WOS:000463887200001
资助机构National Key R&D Project of the Chinese Ministry of Science and Technology ; Key Program of the National Natural Science Foundation of China ; National Natural Science Foundation of China ; Natural Science Foundation of Gansu
源URL[http://119.78.100.186/handle/113462/133640]  
专题中国科学院近代物理研究所
通讯作者Zhang, Hong
作者单位1.Gansu Prov Hosp, Dept Biotherapy Ctr, Lanzhou, Gansu, Peoples R China
2.Chinese Acad Sci, Inst Modern Phys, Dept Radiat Med, Lanzhou, Gansu, Peoples R China
3.Chinese Acad Sci, Inst Modern Phys, Key Lab Heavy Ion Radiat Biol & Med, Lanzhou, Gansu, Peoples R China
4.Univ Chinese Acad Sci, Sch Life Sci, Beijing, Peoples R China
5.Soochow Univ, Med Coll Soochow, Med Sch Radiat Med & Protect, Suzhou, Peoples R China
推荐引用方式
GB/T 7714		 Zhang, Qianjing,Di, Cuixia,Yan, Junfang,et al. Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells[J]. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY,2019,47(1):1273-1280.
APA Zhang, Qianjing.,Di, Cuixia.,Yan, Junfang.,Wang, Fang.,Qu, Tao.,...&Zhang, Hong.(2019).Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells.ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY,47(1),1273-1280.
MLA Zhang, Qianjing,et al."Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells".ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 47.1(2019):1273-1280.

入库方式： OAI收割

来源：近代物理研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。